Posted by Michael Wonder on 27 Apr 2024
Biogen receives positive CHMP opinion for Tofidence (tocilizumab), a biosimilar referencing RoActemra
25 April 2024 - CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing Tofidence to the reference product RoActemra.
Biogen today announced that the CHMP of the EMA adopted a positive opinion for Tofidence (tocilizumab), a biosimilar monoclonal antibody referencing RoActemra.
